Covered recipient · General Payments record
SUSAN M O BRIEN
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
General Payments · PY2018–2024
$408,169.42
- Reported across 310 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $42,440.00 | 21 |
| Food and Beverage | $1,947.45 | 21 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $16,435.63 | 10 |
| Acerta Pharma LLC | $6,156.09 | 5 |
| BeiGene USA, Inc. | $5,431.22 | 9 |
| Sumitomo Pharma America, Inc. | $3,975.00 | 1 |
| Celgene Corporation | $3,150.00 | 2 |
| Kite Pharma, Inc. | $2,620.00 | 2 |
| E.R. Squibb & Sons, L.L.C. | $1,730.00 | 1 |
| GlaxoSmithKline, LLC. | $1,600.00 | 1 |
| Epizyme, Inc. | $1,500.00 | 2 |
| Genentech USA, Inc. | $820.67 | 7 |
| AstraZeneca UK Limited | $820.00 | 1 |
| JAZZ PHARMACEUTICALS INC. | $148.84 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (42)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $40.00 | 01/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105139682 | CMS |
| ABBVIE INC. | $10,350.00 | 01/23/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1105139684 | CMS |
| ABBVIE INC. | $900.00 | 02/21/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1105139686 | CMS |
| ABBVIE INC. | $900.00 | 03/01/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1105139688 | CMS |
| ABBVIE INC. | $54.26 | 05/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105139690 | CMS |
| ABBVIE INC. | $900.00 | 07/09/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1105139692 | CMS |
| ABBVIE INC. | $1,350.00 | 08/15/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1105139694 | CMS |
| ABBVIE INC. | $141.37 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105139696 | CMS |
| ABBVIE INC. | $450.00 | 12/20/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1105139698 | CMS |
| ABBVIE INC. | $1,350.00 | 12/24/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1105139700 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,740.00 | 06/18/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1104442330 | CMS |
| AstraZeneca Pharmaceuticals LP | $46.09 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104338592 | CMS |
| AstraZeneca Pharmaceuticals LP | $30.00 | 12/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104255191 | CMS |
| AstraZeneca Pharmaceuticals LP | $60.00 | 12/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105419730 | CMS |
| AstraZeneca Pharmaceuticals LP | $3,280.00 | 12/23/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1104615190 | CMS |
| AstraZeneca UK Limited | $820.00 | 11/06/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1093970241 | CMS |
| BeiGene USA, Inc. | $1,500.00 | 01/12/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1120858331 | CMS |
| BeiGene USA, Inc. | $76.05 | 06/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120858335 | CMS |
| BeiGene USA, Inc. | $1,875.00 | 06/28/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1120858333 | CMS |
| BeiGene USA, Inc. | $69.28 | 07/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120858343 | CMS |
| BeiGene USA, Inc. | $149.49 | 09/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120858337 | CMS |
| BeiGene USA, Inc. | $46.17 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120858339 | CMS |
| BeiGene USA, Inc. | $102.09 | 12/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120858341 | CMS |
| BeiGene USA, Inc. | $113.14 | 12/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120858345 | CMS |
| BeiGene USA, Inc. | $1,500.00 | 12/18/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1120858347 | CMS |
| Celgene Corporation | $2,100.00 | 01/31/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1101116226 | CMS |
| Celgene Corporation | $1,050.00 | 07/18/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1101116228 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,730.00 | 01/30/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1101350974 | CMS |
| Epizyme, Inc. | $750.00 | 05/17/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1071126044 | CMS |
| Epizyme, Inc. | $750.00 | 08/23/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1071126046 | CMS |
| Genentech USA, Inc. | $119.13 | 02/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133120106 | CMS |
| Genentech USA, Inc. | $149.99 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133120114 | CMS |
| Genentech USA, Inc. | $112.42 | 05/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133120110 | CMS |
| Genentech USA, Inc. | $138.99 | 06/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133120093 | CMS |
| Genentech USA, Inc. | $73.70 | 06/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133120098 | CMS |
| Genentech USA, Inc. | $82.44 | 07/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133120118 | CMS |
| Genentech USA, Inc. | $144.00 | 12/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133120102 | CMS |
| GlaxoSmithKline, LLC. | $1,600.00 | 02/19/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1116643404 | CMS |
| JAZZ PHARMACEUTICALS INC. | $148.84 | 09/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150226376 | CMS |
| Kite Pharma, Inc. | $50.00 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1128614599 | CMS |
| Kite Pharma, Inc. | $2,570.00 | 06/17/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1128614597 | CMS |
| Sumitomo Pharma America, Inc. | $3,975.00 | 03/07/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1148897935 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.